PALI Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 10.38%, SMA50 0.31%, SMA200 39.7%). The stock’s 14-day RSI is 55.31 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.92% below its high and over 249.06% above its low. Average 10-day trading volume of 4.67 million shares is slightly above the 3-month average of 3.83 million, indicating heightened recent market interest.

Palisade Bio, Inc. has 9.12 million shares outstanding. The public float is 8.62 million shares, elevated short interest at 4.68% of float. This equals 424.35 thousand shares. The short ratio is 0.08 days. Institutional investors hold 5.93% of the float. Insiders own 0.24%. JOHE KARL holds 826.30 thousand shares, GARR RICHARD has 240.00 thousand shares and CONRON JOHN has 51.36 thousand shares. Over the past six months, insider transactions show balanced activity. They sold 5.88 thousand shares across 2 transactions.

Palisade Bio, Inc. generated EPS of -$4.22 over the past year. Five-year average earnings growth is 77.35%. Wall Street analysts project EPS growth of 67.97% annually over the next five years. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.04. Next year's EPS is expected at $49.06. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $5.00. The high target offers 792.86% upside. The low target suggests 78.57% downside. The mean target is $10.50. This offers 275.0% upside. Palisade Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 18.75%. The prior quarter beat by 20.83%. Over the last six quarters, Apple has recorded several small beats. These include 13.31% in August 12, 2024.

Palisade Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.39. This means the shares are trading above this model’s fair value.

Palisade Bio, Inc. (NASDAQ:PALI) closed at $2.80 USD, gaining $0.30 (12.00%) from the previous close of $2.50. The stock is currently trading near its 52-week high $0.53 and $2.80. With a market capitalization of about $464.48 million, Palisade Bio, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 3.84 million shares, trading with heavier-than-usual volume. Headquartered in Carlsbad, CA, Palisade Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO J. D. Finley, the company employs approximately 8 people and listed since March 30, 2007. Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract.

Palisade Bio, Inc. trades at a P/E ratio of -9.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.18 suggesting the stock is closer to book value. The P/FCF stands at -41.83, also below market averages.

Our AI price prediction model suggests that Palisade Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.79%, with price expected at $2.75 by May 05, 2026, within a range of $2.61 to $2.90 3-Month Outlook: Projected rise of 77.5%, reaching $4.97 by July 20, 2026, with a range of $4.32 to $5.40. 1-Year Outlook: Projected gain of 283.21%, with price at $10.73 by April 21, 2027, within a range of $7.45 to $11.66.

Palisade Bio, Inc. (NASDAQ:PALI) shares are down -19.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Palisade Bio, Inc. trading at a premium to the broader market with a P/E of -9.07. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $18.95, suggesting 576.79% upside. Our AI forecast model points to short-term weakness (-1.79% over two weeks), a medium-term rise (77.5% over three months), and a longer-term gain (283.21% over one year), with expected trading ranges indicating moderate volatility.